Physician

Danko Martincic, MD

According to 2025 Medicare claims, Danko Martincic, MD (NPI: 1124071592) practices hematology/oncology in the Coeur d'Alene, ID market, with the plurality of this provider's patient population coming from Kootenai, ID. This provider's primary affiliated billing organization is BEACON CANCER CARE PLLC (NPI: 1407335367; TIN: 83-1372781) and primary practice location at 83854-7852. Martincic is affiliated with the Kootenai Accountable Care, LLC (ACO ID: A3621), Caravan Collaborative Pathways (ACO ID: A4604), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Martincic's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 474 traditional Medicare patients, billed 315,005 HCPCS/CPT codes, and received $5,999,652 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,150 prescription claims across 200 beneficiaries totaling $2,989,875 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 25 claims. Open Payments data shows 272 records totaling $616,056. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $3,023,452 to $5,999,652. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $883,284 and ending at $2,989,875. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	820	298,361	$3,023,452
2016	810	330,318	$3,130,253
2017	848	282,495	$3,699,156
2018	933	267,153	$3,519,228
2019	107	537	$9,576
2020	191	34,589	$602,109
2021	396	198,032	$3,185,798
2022	510	287,395	$4,237,760
2023	494	288,500	$6,111,030
2024	474	315,005	$5,999,652

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	222	1,593	$883,284
2016	233	1,390	$1,613,538
2017	228	1,387	$1,713,583
2018	218	1,350	$1,726,339
2019	73	181	$338,592
2020	67	244	$250,748
2021	122	602	$1,616,717
2022	162	909	$2,434,561
2023	179	1,004	$1,851,809
2024	200	1,150	$2,989,875

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	53	187	$44,290
2016	11	123	$36,928
2017	N/R	75	$20,375
2018	N/R	24	$3,616
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	11	$211
2022	N/R	39	$1,380
2023	N/R	N/R	N/R
2024	N/R	25	$501

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	154	849	$134
96413	Administration of chemotherapy into vein, 1 hour or less	113	739	$94
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	289	931	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	201	361	$62
96375	Injection of additional new drug or substance into vein	100	1,110	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	37	1,092	$537,422
Revlimid	Lenalidomide	37	977	$408,820
Pomalyst	Pomalidomide	20	560	$360,039
Nubeqa	Darolutamide	20	600	$253,275
Lenalidomide	Lenalidomide	18	483	$164,604

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$263
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$238

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	255	$138,983	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	17	$477,073	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Danko Martincic, MD?

Tedicare shows public-source Medicare data for Danko Martincic, MD (NPI 1124071592), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Danko Martincic, MD have ACO affiliation data?

Danko Martincic, MD is shown with ACO affiliation data for Kootenai Accountable Care, LLC (MSSP, ACO ID A3621), Caravan Collaborative Pathways (MSSP, ACO ID A4604), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Danko Martincic, MD?

Danko Martincic, MD is linked to BEACON CANCER CARE PLLC (billing NPI 1407335367) in the available physician profile data.

Does Danko Martincic, MD have Open Payments data?

Danko Martincic, MD has 272 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.